© 2023 BioMarin. All rights reserved.

BioMarin is committed to transparency into environment, social and governance (ESG) activities at our company. In 2022, we took several additional actions to advance our commitment to ESG issues, including:

  • Formed an internal cross-functional team of organizational leaders whose purpose is to respond to and begin to address stakeholder feedback received on all ESG issues. The cross-functional ESG Core Team is overseen by an ESG Executive Steering Committee comprised of top executives, including our chief company officers for legal, compliance, finance/investor relations, technical operations, people and communications. In addition, the BioMarin Board of Directors’ Corporate Governance Nominating Committee provides further oversight of all ESG activities.
  • Hired an independent consulting firm with expertise in ESG risk management and disclosure to provide technical advice to the cross-functional team.
  • Disclosed additional ESG information on BioMarin.com.
  • Completed an MSCI gap analysis.
  • Completed a limited materiality assessment, which identified the ESG topics most important to our business and
  • Compiled and analyzed information deemed financially material by SASB’s Biotechnology & Pharmaceuticals, Sustainability Accounting Standard, Version 2018-10, and published a SASB index on BioMarin.com with hyperlinks to more detailed corporate responsibility narratives included throughout our website.

From this work, BioMarin plans to complete the following additional actions by 2025:

  • Monitor changes in MSCI score and gauge investor feedback as more information is disclosed, and report back on progress.
  • Publish a formal ESG report.
  • Develop and implement additional ESG goals and initiatives.
Image: Little girl making a heart with her hands
Careers at BioMarin

Our focus on rare disease gives us the rare opportunity to truly impact lives.

Learn More about careers with BioMarin